Aurinia’s mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease. We believe strong collaboration powers success at every level of drug development and commercialization. We are committed to forging strategic partnerships aligned with our mission to help advance groundbreaking therapies for people in need.
Aurinia is focused on advancing new therapies for people with autoimmune diseases through licensing, acquiring or partnering clinical-stage assets as well as developing infrastructure to advance our commercial therapy.
In 2020, Aurinia entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of lupus nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Lichtenstein and Ukraine.
For inquires related to strategic partnerships, please contact: email@example.com.